Experimental drug offered to patients with rare gut condition
NCT ID NCT05232110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study provides compassionate access to pozelimab for people with CD55-deficient protein-losing enteropathy, a rare condition where the gut leaks proteins. The goal is to offer an experimental treatment option when no other therapies are available. Participants receive the drug under close medical supervision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-DEFICIENT PROTEIN-LOSING ENTEROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.